News | October 02, 2012

Riverain Issued Patents for New Software Cancer Imaging Filters

RiverainClearRead Bone Suppression ClearRead + Detect X-Ray

October 2, 2012 — Riverain Technologies, an industry leader and innovator in proprietary image processing and machine learning technologies, announced that the United States Patent and Trademark Office (USPTO) has awarded the company broad patents for its technologies, opening the door for the company’s software to be used in wider healthcare applications and in other industries. These two new patents not only protect Riverain’s novel chest X-ray technology, which suppresses bone and calls out suspicious tissue, but also hold enormous promise for the company to bring its breakthrough software to other medical applications, including; computed tomography (CT) scans, magnetic resonance imaging (MRI) and ultrasound.

Riverain has been issued U.S. Patent 8,204,292 for its methodology to selectively remove unwanted objects, or features, within images. The technology is used in the company’s premier software, ClearRead Bone Suppression, which suppresses the ribs and clavicles in a chest X-ray image resulting in the formation of a soft tissue image of the chest. The application provides radiologists with a clearer, unobstructed view of the chest to aid in early detection of lung disease, including lung cancer. Currently employed in chest X-ray, a range of possible applications exists within other imaging modalities including CT, MRI, positron emission tomography (PET), full field digital mammography and tomosynthesis. For example, the methodology has been successfully applied to remove and equalize the tissue in the pectoral muscle in a mammography image.

Riverain’s patented feature suppression technology is ideal for use in a variety of industries outside medical as well, including military, travel, industrial and document processing applications.

In addition, Riverain was issued U.S. Patent 8,160,335 for its proprietary computer-aided diagnosis (CAD) methodology on software or hardware derived images, such as dual energy subtracted soft tissue images and/or bone suppressed images. The technology is used in the company’s ClearRead +Detect software, an application that identifies and circles potentially cancerous lung nodules on a bone-suppressed chest X-ray image, and/or images captured by modalities such as dual energy subtraction (DES). ClearRead +Detect has been clinically proven to improve the detection of 9-30mm lung nodules and allow the detection of up to one in two previously missed lung nodules.[1]

“These recently issued patents cover some of the methods and processes that give our market-leading software solutions a distinct advantage,” said Steve Worrell, Riverain’s chief technology officer. “Riverain now has an intellectual property portfolio of more than 15 issued or pending patents and welcomes inquiries regarding applications inside and outside the medical field.”

[1] Riverain Medical OnGuard FDA PMA Reader Study Results 2009

For more information: www.RiverainTechnologies.com

Related Content

HealthMyne QIDS Platform Adds Cancer Screening Module
Technology | Clinical Decision Support | August 21, 2018
HealthMyne announced the release of Quantitative Imaging Decision Support (QIDS) 5 featuring a new, automated Cancer...
Nuance Launches Cloud-Based mPower Clinical Analytics Platform at AHRA 2018
Technology | Analytics Software | August 16, 2018
At the Association for Medical Imaging Management (AHRA) 2018 Annual Meeting and Exposition, July 22-25 in Orlando, Fla...
Intel and Philips Demonstrate CPU Ability in Deep Learning Inference Test Cases
News | Artificial Intelligence | August 15, 2018
Intel and Philips recently tested two healthcare uses for deep learning inference models using Intel Xeon Scalable...
Guerbet Partners With Imalogix on Dose Optimization With Artificial Intelligence
News | Radiation Dose Management | August 14, 2018
August 14, 2018 — Guerbet LLC USA announced a commercial partnership with Imalogix, a provider of...
Visage Signs Mercy for Visage 7 Open Archive
News | Enterprise Imaging | August 09, 2018
Visage Imaging Inc. announced that it has signed a seven-year contract with Mercy, the fifth largest Catholic health...
Videos | Radiomics | August 09, 2018
A discussion with Martin Vallieres, Ph.D., post-doctoral fellow at McGill University, Montreal, Canada.
Aidoc Receives FDA Clearance for AI Detection of Acute Intracranial Hemorrhage
Technology | Clinical Decision Support | August 08, 2018
Aidoc announced that it was granted U.S. Food and Drug Administration (FDA) clearance for the first product of its...
Metro Health-University of Michigan Health Partners With Eon to Improve Lung Cancer Care
News | Oncology Diagnostics | August 07, 2018
Metro Health-University of Michigan Health announced it is partnering with healthcare data company Eon to improve the...
Artificial Intelligence in Medical Imaging to Top $2 Billion by 2023
News | Artificial Intelligence | August 06, 2018
The world market for machine learning in medical imaging is set for a period of robust growth and is forecast to top $2...
Imalogix Brings Fluoroscopy Capabilities to Radiation Dose Management Platform
Technology | Radiographic Fluoroscopy (RF) | August 06, 2018
Imalogix, a provider of artificial intelligence (AI) process and workflow solutions, announced the availability of the...
Overlay Init